文献速递前列腺癌

转移性去势初治前列腺癌患者负担:识别更可能从早期多西他赛获益的男性——CHAARTED与GETUG-AFU15研究的进一步分析

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
PubMed 文献 · Eur Urol · 2018-02-21

该研究汇总CHAARTED和GETUG-AFU15两项III期试验数据,按转移负荷(高瘤负荷HV和低瘤负荷LV)及转移发生时间(初诊或既往局部治疗后)分层,分析早期多西他赛联合ADT的生存获益。结果显示HV患者联合多西他赛显著改善总生存(合并HR 0.68,95%CI 0.56-0.82,p<0.001),而LV患者未见生存获益(合并HR 1.03,95%CI 0.77-1.38),且HV与LV亚组间效应存在显著异质性(p=0.017)。

要点

  • 高瘤负荷转移性去势初治前列腺癌患者,早期多西他赛联合ADT可显著改善总生存。
  • 低瘤负荷患者未观察到多西他赛的生存获益,且可能承受不必要的毒性。
  • 转移发生时间(初诊或既往局部治疗后)不影响早期多西他赛的疗效异质性。

核心结论

  • 在CHAARTED和GETUG-AFU15研究中,低瘤负荷患者接受早期多西他赛未见明显生存获益。
  • 两项研究一致显示,高瘤负荷患者接受早期多西他赛可改善总生存。

研究设计与样本

  • 汇总两项独立III期随机试验(GETUG-AFU15,N=385;CHAARTED,N=790)的聚合数据。
  • 比较ADT单药与ADT联合多西他赛,按统一标准定义高瘤负荷和低瘤负荷。
  • GETUG-AFU15和CHAARTED幸存者中位随访时间分别为83.2个月和48.2个月。

主要发现

  • 高瘤负荷患者:CHAARTED中ADT组中位OS 34.4个月,ADT+D组51.2个月;GETUG-AFU15中ADT组35.1个月,ADT+D组39.8个月;合并HR 0.68(95%CI 0.56-0.82,p<0.001)。
  • 低瘤负荷患者:CHAARTED中ADT组未达到,ADT+D组63.5个月;GETUG-AFU15中ADT组83.4个月,ADT+D组未达到;合并HR 1.03(95%CI 0.77-1.38)。
  • 高瘤负荷与低瘤负荷亚组间ADT+D与ADT效应量存在显著异质性(p=0.017)。
  • 初诊转移与既往局部治疗后转移亚组间未见显著异质性(p=0.4)。

关键数值与推荐

  • 高瘤负荷患者早期多西他赛改善中位OS的合并HR为0.68(95%CI 0.56-0.82,p<0.001)。
  • 低瘤负荷患者早期多西他赛的合并HR为1.03(95%CI 0.77-1.38),无生存获益证据。

临床怎么用

  • 对高瘤负荷转移性去势初治前列腺癌患者,可考虑在ADT起始时联合多西他赛以改善生存。
  • 对低瘤负荷患者,早期多西他赛的毒性可能超过获益,应谨慎选择。

局限性

  • 该分析为基于两项独立III期随机试验聚合数据的亚组分析。
  • 低瘤负荷亚组的分析为事后分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early D. OBJECTIVE: To define the overall survival (OS) of aggregate data of patient subgroups from the CHAARTED and GETUG-AFU15 studies, defined by metastatic burden (HV and LV) and time of metastasis occurrence (at diagnosis or after prior local treatment [PRLT]). DESIGN, SETTING, AND PARTICIPANTS: Data were accessed from two independent phase III trials of ADT alone or ADT+D-GETUG-AFU15 (N=385) and CHAARTED (N=790), with median follow-ups for survivors of 83.2 and 48.2 mo, respectively. The definition of HV and LV disease was harmonized. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was OS. RESULTS AND LIMITATIONS: Meta-analysis results of the aggregate data showed significant heterogeneity in ADT+D versus ADT effect sizes between HV and LV subgroups (p=0.017), and failed to detect heterogeneity in ADT+D versus ADT effect sizes between upfront and PRLT subgroups (p=0.4). Adding D in patients with HV disease has a consistent effect in improving median OS (HV-ADT: 34.4 and 35.1 mo, HV-ADT+D: 51.2 and 39.8 mo in CHAARTED and GETUG-AFU15, respectively; pooled average hazard ratio or HR (95% confidence interval [CI]) 0.68 ([95% CI 0.56; 0.82], p<0.001). Patients with LV disease showed much longer OS, without evidence that D improved OS (LV-ADT: not reached [NR] and 83.4; LV-ADT+D: 63.5 and NR in CHAARTED and GETUG-AFU15, respectively; pooled HR (95% CI) 1.03 (95% CI 0.77; 1.38). Aggregate data showed no evidence of heterogeneity of early D in LV and HV subgroups irrespective of whether patients had PRLT or not. Post hoc subgroup analysis was based on aggregated data from two independent phase III randomized trials. CONCLUSIONS: There was no apparent survival benefit in the CHAARTED and GETUG-AFU15 studies with D for LV. Across both studies, early D showed consistent effect and improved OS in HV patients. PATIENT SUMMARY: Patients with a higher burden of metastatic prostate cancer starting androgen deprivation therapy (ADT) have a poorer prognosis and are more likely to benefit from early docetaxel. Low-volume patients have longer overall survival with ADT alone, and the toxicity of docetaxel may outweigh its benefits.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gravis G, Boher JM, Chen YH, et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018. PMID: 29475737. doi:10.1016/j.eururo.2018.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。